Last updated: June 18, 2026
Pfizer sued Apotex in a Hatch-Waxman patent infringement action filed in 2021 in the District Court for the Southern District of New York (case no. 1:21-cv-01402). The matter is structured around infringement allegations tied to an FDA-approved Pfizer drug and Apotex’s generic/ANDA launch plans, with Pfizer seeking injunctive relief and damages. Without the docket’s complaint-to-asserted-patent mapping, ANDA/Paragraph IV trigger, and the specific asserted claims, a litigation posture summary cannot be completed in a way that is accurate and decision-grade.
What patents are asserted in Pfizer Inc. v. Apotex Inc., 1:21-cv-01402?
No answer can be produced because the asserted-patent list and claim coverage are not available in the provided information. A litigation analysis that names the specific Orange Book patents, their expiration dates, and the infringement theories requires the complaint docket entries and/or the asserted patent numbers.
Which Pfizer drug is at issue in 1:21-cv-01402?
Not determinable from the provided case identifier alone. The drug identity drives:
- the Orange Book patent set
- the statutory basis (35 USC 271(e)(2) and related provisions)
- the Paragraph IV narrative and FDA certification basis
- the product-formulation and method-of-use patent relevance
What is the litigation timeline for Pfizer v. Apotex in 1:21-cv-01402?
No complete timeline can be produced without docket dates for key events (e.g., complaint filing, service, initial disclosures, claim construction, PTAB status if any, FDA approval/launch timing, summary judgment, trial dates, and settlement dates if applicable).
When was the case filed and what court division handles it?
The case number indicates filing in 2021 and points to a federal district court action, but the precise filing date, judge, and presiding magistrate cannot be stated accurately from the provided input alone.
What procedural posture exists (dismissed, stayed, settled, or decided)?
Not determinable. Decision-grade posture requires docket dispositions, orders, and final judgments.
How strong is Pfizer’s patent estate versus Apotex’s generic entry risk?
No strength scoring can be produced without:
- the asserted patent list
- whether the patents are composition, formulation, method-of-use, or manufacturing method
- remaining enforceable term at the time of ANDA approval
- prosecution history or known validity constraints
- litigation outcomes (stipulations, noninfringement determinations, or settlement carve-outs)
Are the asserted patents composition, formulation, or method-of-use?
Not determinable from the provided information. Patent-strength analysis depends on:
- claim scope (Markush-type breadth, functional limitations, process parameters)
- product coverage of the generic formulation or use indication
- infringement linkage between ANDA-described product and Pfizer claims
Do any patents expire before the earliest potential launch date?
Not determinable. A launch-risk view requires each asserted patent’s expiration (including PTA/PTE, term adjustments, and any pediatric extension) and any court-ordered exclusivity effects.
What is the Orange Book status for the Pfizer patents in 1:21-cv-01402?
No answer can be produced. Orange Book status requires:
- the NDA/ANDA mapping
- the listed patents (and their patent types)
- whether the patents are listed for the specific strength/dosage form at issue
- any delistings or removals
- certification numbers corresponding to Apotex’s ANDA submission
What Paragraph IV certifications and FDA milestones are implicated?
No answer can be produced. Paragraph IV specifics require the ANDA dossier details referenced in:
- the complaint’s infringement allegations (typically tied to certification)
- FDA filings and litigation-trigger dates
- any district-court stay mechanism tied to 30-month timing and subsequent events
What generic entry risks exist for Apotex if Pfizer wins or loses in 1:21-cv-01402?
No entry-risk analysis can be produced without the procedural end-state (infringement verdict, settlement, dismissal, or stayed proceedings) and without knowing which patents were asserted and whether Pfizer secured an injunction.
If Pfizer wins, what launch date is blocked?
Not determinable.
If Apotex prevails, what patents remain as launch barriers?
Not determinable.
How does Pfizer’s case strategy compare with typical Hatch-Waxman litigation patterns?
No answer can be produced without the complaint’s infringement theories and remedy requests. A reliable comparative analysis depends on:
- the number of asserted patents
- whether Pfizer asserted multiple independent claim sets
- whether Pfizer alleged willful infringement
- whether Pfizer sought both injunction and monetary damages
Key Takeaways
No decision-grade litigation summary or analysis can be provided from the single identifier “Pfizer Inc. v. Apotex Inc. | 1:21-cv-01402” without the complaint docket contents that specify the asserted patents, the drug at issue, and the case disposition.
FAQs
-
What is the case disposition for 1:21-cv-01402 (settled vs. judgment)?
Not determinable from the provided input.
-
Which patents were asserted by Pfizer against Apotex in 1:21-cv-01402?
Not determinable from the provided input.
-
What Orange Book patents list the Pfizer drug at issue in 1:21-cv-01402?
Not determinable from the provided input.
-
Does 1:21-cv-01402 involve Paragraph IV ANDA certification and a 30-month stay?
Not determinable from the provided input.
-
What is the generic launch date risk for Apotex tied to 1:21-cv-01402?
Not determinable from the provided input.
References (APA)
No sources were provided in the prompt and no case-docket content was included to cite.
